Herantis Pharma (OHEL:HRTIS) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:HRTIS Herantis Pharma PLC OHEL:HRTIS
27 GF Score
Price €1.63
! 3 Warning Signs
View Full Analysis

What is Herantis Pharma FFO?

FFO (Funds from operations) only applies to REITs.

OHEL:HRTIS
27GF Score
Herantis Pharma PLC OHEL:HRTIS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Herantis Pharma Business Description

Address Bertel Jungin Aukio 1, Espoo, FIN, 02600
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinsons disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
27GF Score

Get the complete analysis for OHEL:HRTIS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price